IP Library Granted Patent US 8,916,705
Granted Patent B2
US 8,916,705 · App. 13/652,164 · Granted Dec 23, 2014

Procaspase-activating compounds and compositions

Inventor: Paul J. Hergenrother (Champaign, IL)
Assignee: The Board of Trustees of the University of Illilnois
C07D295/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,705
App. No.
13/652,164
Granted
Dec 23, 2014
Kind
B2
Abstract

The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

Claims (15)

1. A compound that directly activates procaspase-3 upon contacting procaspase-3, wherein the compound is a novel compound of Formula I:

wherein

R 1 is a substituted (aryl)methylene, or (aryl)methine wherein the methine carbon is optionally substituted with phenyl;

n is 2;

each R 2 is methyl, ethyl or t-butyl or two R 2 groups form an ortho-fused benzo group; and

wherein R 1 is substituted (aryl)methylene, the (aryl)methylene substitution comprises one or more nitro, sulfonamide, azidomethylene, phenoxy, phenyl, trifluoromethyl, trifluoromethoxy, phenylsulfonylmethylene, benzoyl, or a combination thereof;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1 wherein each R 2 is t-butyl.

3. The compound of claim 1 wherein R 1 is (aryl)methine wherein the methine carbon is substituted with phenyl.

4. The compound of claim 1 wherein R 1 is:

5. The compound of claim 1 wherein the compound induces death of cancer cells in culture.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.

7. The compound:

8. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable diluent, excipient, or carrier, wherein the compound is:

or a pharmaceutically acceptable salt or solvate thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2014
From: HERGENROTHER, PAUL J.
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 032031/0546 →
Continuity (2)
Provisional Application 61547135 · Oct 14, 2011
Related Publication 20130096133A1 · Apr 18, 2013